Setback for Graspa for acute lymphoblastic leukemia
The French company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, saw its shares plunge 23.8% to 13.31 euros this morning after it announced a negative development for its lead product candidate.
French biotech firm Erytech Pharma (Euronext Paris: ERYP) said it has decided to withdraw the current European Marketing Authorization Application (MAA) for Graspa (eryaspase) for the treatment of acute lymphoblastic leukemia (ALL).
The company determined that the time allowed in the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) procedure was not sufficient to provide the additional data requested in the CHMP’s Day 180 List of Outstanding Issues (LOI).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze